Intercure (TSX:INCR.U) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Intercure FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Intercure's Free Cash Flow for the three months ended in Dec. 2024 was $0.00 Mil. Intercure's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Intercure's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Intercure's current FCF Yield % is -25.93%.

The historical rank and industry rank for Intercure's FCF Margin % or its related term are showing as below:

TSX:INCR.U' s FCF Margin % Range Over the Past 10 Years
Min: -444.92 Med: -19.91 Max: 8.11
Current: -29.85

During the past 13 years, the highest FCF Margin % of Intercure was 8.11%. The lowest was -444.92%. And the median was -19.91%.

TSX:INCR.U's FCF Margin % is ranked worse than
85.07% of 971 companies
in the Drug Manufacturers industry
Industry Median: 0.87 vs TSX:INCR.U: -29.85

Intercure FCF Margin % Historical Data

The historical data trend for Intercure's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercure FCF Margin % Chart

Intercure Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-19.91

7.33

8.11

-15.82

-29.85

Intercure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-50.13	-	-	-	-

Competitive Comparison of Intercure's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intercure's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intercure's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Intercure's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Intercure FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Intercure's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-21.053	/	70.524
	=	-29.85 %

Intercure's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0
	=	%

Intercure FCF Margin % Related Terms

Thank you for viewing the detailed overview of Intercure's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intercure Ltd (TSX:INCR.U) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

INCR:USA INCR:Israel

Address

85 Medinat ha-Yehudim Street, Herzliya, ISR, 4676670

Website

https://www.intercure.co

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

Intercure Headlines

No Headlines